Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML

Twelve to 22% of pediatric acute myeloid leukemia (AML) patients present with hyperleukocytosis, which is one of the main risk factors of early death due to its clinical complications: leukostasis, causing pulmonary or central nervous system injuries, tumor lysis syndrome, and disseminated intravasc...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Franziska, Erlacher, Miriam, Niemeyer, Charlotte, Reinhardt, Dirk, Klusmann, Jan-Henning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681922/
https://www.ncbi.nlm.nih.gov/pubmed/36440328
http://dx.doi.org/10.3389/fped.2022.1046586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681922/
https://www.ncbi.nlm.nih.gov/pubmed/36440328
http://dx.doi.org/10.3389/fped.2022.1046586

Ejemplares similares